{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:07:02Z","timestamp":1790089622142,"version":"4.0.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastatic uveal melanoma (mUM) carries a poor prognosis, with low response rates to checkpoint inhibitors. The phase III first-line IMCgp100-202 trial established tebentafusp, a bi-specific T cell engager, as the first treatment to demonstrate a survival benefit in mUM. Here, we report retrospective real-world efficacy and toxicity outcomes from the tebentafusp United Kingdom Expanded Access Programme (UK EAP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>115 HLA-A*02:01 positive patients with mUM were treated between July 2021 and June 2023. 10 of 18 UK EAP centres submitted data, and outcomes for 88 patients are reported here. Data was collected on demographics, disease characteristics, survival, and treatment toxicities and analyzed to identify factors impacting on median overall survival (mOS), median progression-free survival (mPFS), occurrence of cytokine release syndrome (CRS) and grade 3\/4 rash.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>71% of patients were treated in the first-line setting, with 94% having liver metastases. At a median follow-up of 12\u2009months (range 0 to 34), mOS was 21\u2009months (95% CI, 17 to NR), and mPFS was 2.76\u2009months (95% CI, 2.53-3.22). The 12-month overall survival rate was 75% (95% CI, 66.11-85.6). Lower lactate dehydrogenase (LDH) and lower liver metastatic burden showed a trend towards improved overall survival, with baseline LDH \u22652\u00d7 ULN conferring a very poor prognosis. Lower liver metastatic burden also associated with reduced frequency of CRS. No\u2009\u2265\u2009grade 3 toxicity was observed beyond dose 5.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tebentafusp on the UK EAP showed comparable real-world efficacy to the phase III first-line trial data, with manageable toxicities having implications for resource planning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag341","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:23:24Z","timestamp":1787570604000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy and toxicity of tebentafusp in metastatic uveal melanoma patients treated on the United Kingdom expanded access programme"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8182-0059","authenticated-orcid":false,"given":"Magdalene","family":"Joseph","sequence":"first","affiliation":[{"name":"Mount Vernon Cancer Centre , Northwood, HA6 2RN,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Tharakan","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre , Northwood, HA6 2RN,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemma","family":"Proudfoot-Jones","sequence":"additional","affiliation":[{"name":"Clatterbridge Cancer Centre , Wirral, CH63 4JY,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J","family":"Sacco","sequence":"additional","affiliation":[{"name":"Clatterbridge Cancer Centre , Wirral, CH63 4JY,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2358-9730","authenticated-orcid":false,"given":"Andrew","family":"Furness","sequence":"additional","affiliation":[{"name":"The Royal Marsden Hospital , London, SW3 6JJ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McMahon","sequence":"additional","affiliation":[{"name":"The Royal Marsden Hospital , London, SW3 6JJ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Khoja","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust , Birmingham, B15 2GW,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1112-4829","authenticated-orcid":false,"given":"Lalit","family":"Pallan","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust , Birmingham, B15 2GW,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2664-902X","authenticated-orcid":false,"given":"Patricio","family":"Serra","sequence":"additional","affiliation":[{"name":"The Christie Hospital , Manchester, M20 4BX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulani","family":"Ranatunge","sequence":"additional","affiliation":[{"name":"Castle Hill Hospital , Cottingham, HU16 5JQ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bode","family":"Oladipo","sequence":"additional","affiliation":[{"name":"Belfast City Hospital , Belfast, BT9 7AB,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Clements","sequence":"additional","affiliation":[{"name":"Belfast City Hospital , Belfast, BT9 7AB,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0311-1181","authenticated-orcid":false,"given":"Lavanya","family":"Mariappan","sequence":"additional","affiliation":[{"name":"Newcastle Freeman Hospital , Newcastle upon Tyne, NE7 7DN,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Hennah","sequence":"additional","affiliation":[{"name":"Newcastle Freeman Hospital , Newcastle upon Tyne, NE7 7DN,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Talbot","sequence":"additional","affiliation":[{"name":"Royal Cornwall Hospital , Truro, TR1 3LJ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Nobes","sequence":"additional","affiliation":[{"name":"Norfolk and Norwich University Hospital , Norwich, NR4 7UY,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Carter","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre , Northwood, HA6 2RN,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Shaw","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre , Northwood, HA6 2RN,","place":["United Kingdom"]},{"name":"University College London Hospitals , London, NW1 2BU,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nathan","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre , Northwood, HA6 2RN,","place":["United Kingdom"]},{"name":"University College London Hospitals , London, NW1 2BU,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"2026092210511884100_oyag341-B1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res"},{"key":"2026092210511884100_oyag341-B2","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"key":"2026092210511884100_oyag341-B3","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1200\/PO.21.00084","article-title":"Positive association between location of melanoma, ultraviolet signature, tumor mutational burden, and response to anti-PD-1 therapy","volume":"5","author":"Dousset","year":"2021","journal-title":"JCO Precis. Oncol"},{"key":"2026092210511884100_oyag341-B4","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1002\/cncr.31345","article-title":"Melanoma: what do all the mutations mean?","volume":"124","author":"Davis","year":"2018","journal-title":"Cancer."},{"key":"2026092210511884100_oyag341-B5","doi-asserted-by":"publisher","first-page":"17588359231160140","DOI":"10.1177\/17588359231160140","article-title":"Tebentafusp: a first-in-class treatment for metastatic uveal melanoma","volume":"15","author":"Howlett","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"2026092210511884100_oyag341-B6","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat Med"},{"key":"2026092210511884100_oyag341-B7","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"2026092210511884100_oyag341-B8","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026092210511884100_oyag341-B9","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.3390\/cancers15133430","article-title":"Tebentafusp in patients with metastatic uveal melanoma: a Real-Life retrospective multicenter study","volume":"15","author":"Tomsitz","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026092210511884100_oyag341-B10","doi-asserted-by":"publisher","first-page":"e21583","DOI":"10.1200\/JCO.2023.41.16_suppl.e21583","article-title":"Tebentafusp (tebe) in a real-world cohort of 72 french metastatic uveal melanoma (UM) patients (pts)","volume":"41","author":"Piperno-Neumann","year":"2023","journal-title":"JCO."},{"key":"2026092210511884100_oyag341-B11","doi-asserted-by":"publisher","first-page":"115634","DOI":"10.1016\/j.ejca.2025.115634","article-title":"Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN expert centres","volume":"227","author":"van der Kooij","year":"2025","journal-title":"Eur J Cancer."},{"key":"2026092210511884100_oyag341-B12","author":"Study Details. A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp | ClinicalTrials.gov"},{"key":"2026092210511884100_oyag341-B13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"2026092210511884100_oyag341-B14","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1158\/1078-0432.CCR-25-1513","article-title":"Incidence and management of adverse events associated with tebentafusp treatment in metastatic uveal melanoma: pooled safety analysis of 410 patients","volume":"31","author":"Sato","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026092210511884100_oyag341-B15","doi-asserted-by":"publisher","first-page":"9584","DOI":"10.1200\/JCO.2022.40.16_suppl.9584","article-title":"Analysis of the effect of systemic corticosteroids on survival from tebentafusp in a phase 3 trial of metastatic uveal melanoma","volume":"40","author":"Ikeguchi","year":"2022","journal-title":"JCO."},{"key":"2026092210511884100_oyag341-B16","doi-asserted-by":"publisher","first-page":"115161","DOI":"10.1016\/j.ejca.2024.115161","article-title":"Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11\/GNAQ mutant melanocytic tumors","volume":"214","author":"Dimitriou","year":"2025","journal-title":"Eur J Cancer."},{"key":"2026092210511884100_oyag341-B17","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3390\/cancers11071007","article-title":"Metastatic uveal melanoma: Treatment strategies and survival\u2014results from the Dutch melanoma treatment registry","volume":"11","author":"Jochems","year":"2019","journal-title":"Cancers (Basel)"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag341\/70784374\/oyag341.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag341\/70784374\/oyag341.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag341\/70784374\/oyag341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:51:22Z","timestamp":1790088682000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag341\/8770367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag341","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,25]]},"article-number":"oyag341"}}